Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632
This examiner grants 45% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17769712 | USE OF MOG FOR PRIMING A TREATMENT FOR GLIOBLASTOMA | Non-Final OA | The Regents of the University of California |
| 17920069 | NON-HUMAN ANIMALS HAVING A HUMANIZED CXCL13 GENE | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18022538 | METHOD FOR SCREENING IN VITRO POPULATION OF STEM CELL DERIVED BETA LIKE CELLS AND NOVEL MARKERS THEREOF | Non-Final OA | Novo Nordisk A/S |
| 16985090 | Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation | Non-Final OA | ImmunityBio, Inc. |
| 17288628 | SYSTEMS AND BREEDING METHODS FOR PEST CONTROL | Final Rejection | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17995043 | METHOD FOR SEPARATING PITUITARY HORMONE-PRODUCING CELLS AND PROGENITOR CELLS THEREOF | Final Rejection | National University Corporation Tokai National Higher Education and Research System |
| 17922731 | USE OF CD34 AS A MARKER FOR SINOATRIAL NODE-LIKE PACEMAKER CELLS | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18571505 | METHODS OF PROCESSING ADULT NEURAL CELLS FROM MAMMALS AND ASSAYS THEREOF | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 17633321 | Engineered CRISPR/Cas9 Systems for Simultaneous Long-term Regulation of Multiple Targets | Non-Final OA | The Penn State Research Foundation |
| 18001277 | TREM2 CHIMERIC RECEPTOR | Non-Final OA | KING'S COLLEGE LONDON |
| 17441602 | BRAIN BLOOD VESSEL MODEL AND DEVICE | Non-Final OA | OSAKA UNIVERSITY |
| 18171862 | METHOD FOR PRODUCING THREE-DIMENSIONAL CELL STRUCTURE, AND THREE-DIMENSIONAL CELL STRUCTURE | Non-Final OA | TOPPAN Inc. |
| 17310051 | FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER IMMUNOTHERAPY | Non-Final OA | Figene, LLC |
| 18038734 | EFFICIENT AND RAPID SPECIFICATION OF SPINAL NEURONAL SUBTYPES FROM HUMAN PLURIPOTENT STEM CELLS | Non-Final OA | UNIVERSITÉ PARIS-SACLAY |
| 17666390 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | Non-Final OA | EDITAS MEDICINE, INC. |
| 17371017 | MYBPC3 POLYPEPTIDES AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 16826102 | METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCY | Non-Final OA | Allogene Therapeutics, Inc. |
| 17049218 | GROWTH INHIBITOR | Final Rejection | Orizuru Therapeutics, Inc. |
| 17040951 | ENGINEERED IMMUNE EFFECTOR CELLS AND USE THEREOF | Non-Final OA | FATE THERAPEUTICS, INC. |
| 18019754 | SPHEROID GENERATOR, SPHEROID CULTURE KIT, AND SPHEROID CULTURE METHOD | Non-Final OA | RESEARCH AND BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY |
| 18002634 | CELL CONSTRUCT COMPRISING SCHWANN CELLS OR SCHWANN CELL-LIKE CELLS AND A BIOCOMPATIBLE MATRIX | Non-Final OA | FACHHOCHSCHULE TECHNIKUM WIEN |
| 17927365 | AXIAL STEM CELLS, METHODS OF PRODUCING AND USES THEREOF | Non-Final OA | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) |
| 17800958 | METHODS AND COMPOSITIONS FOR MODULATING ARGININE LEVELS IN IMMUNE CELLS | Non-Final OA | Sky Perfect International Limited |
| 17257221 | METHOD FOR IN VITRO REPROGRAMMING OF FIBROBLASTS INTO SERTOLI CELLS AND APPLICATION THEREOF | Final Rejection | EVERLIFE BIOMED CO. LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy